Wednesday, July 6, 2022
Retail
No Result
View All Result
  • Biomedical
    • All
    • Biomedical interviews
    • Biomedical news
    • Biomedical reports
    Europa lleva la delantera en el desarrollo y comercialización de los medicamentos biosimilares: nuevas licencias y un gran ahorro en el horizonte

    Europe leads the way in the development and commercialization of biosimilar medicines: new licenses and huge savings on the horizon

    Biotecnología al servicio de la agricultura sostenible: Biorizon biotech y los proyectos H2020 SABANA y BACAGRO

    New tests of early cancer detection will allow the implementation of better treatments through personalized medicine

    La medicina predictiva utiliza el asesoramiento genético para medir la probabilidad de las enfermedades que se pueden padecer y cómo prevenirlas

    Predictive medicine uses the genetic counselling to measure the likelihood of illnesses that can be suffer and how to prevent them

  • Agri-food
    • All
    • Agri-food news
    • Agri-food reports
    Agrobiotechnology: the keys of the sector that mostly is going to impact in our future

    Agrobiotechnology: the keys of the sector that mostly is going to impact in our future

    Alimentos funcionales para suplir la deficiencia de la enzima intestinal DAO: el remedio contra las migrañas

    Functional food to supply the deficiency of the intestinal enzyme DAO: the remedy against migraines

    Los biopesticidas de esta biotech chilena permiten combatir el perjudicial hongo Botrytis cinerea.

    These biopesticides from this Chilean biotech allow to combat harmful fungus Botrytis cinerea.

  • Industrial
    • All
    • Industrial news
    Horizonte H2020 se extiende hasta 2027: Descubre cómo se optimizan los proyectos de investigación con esta estrategia

    Horizon H2020 extends to 2027: Discover how are optimized research projects with this strategy

    El proyecto europeo IBISBA 1.0 hace que la biotecnología industrial abra sus puertas a la investigación.

    The European project IBISBA 1.0 makes that industrial biotechnology opens its doors to the investigation.

    La posibilidad de oro en España para su mejora bioeconómica tiene nombre: “Biorrefinerías”.

    Golden opportunity in Spain for its bioeconomic improvement has name: “Biorefineries”.

  • Bioinformatics
    • All
    • Bioinformatics news
    • Bioinformatics reports
    La STATegra Summer School llega a su fin tras 5 intensivos días de aplicación de técnicas bioinformáticas a la integración de datos ómicos

    The STATegra Summer School comes to its end after 5 days of intensive application of bioinformatics techniques for omics data integration

    Let us go deep into the biological systems technology, what is its potential and which tools are now affordable

    Let us go deep into the biological systems technology, what is its potential and which tools are now affordable

    La atención médica virtual extiende sus redes y surgen monopolios sobre la asistencia médica: descubre el por qué y qué consecuencias puede traernos.

    Virtual health care extends its networks and arise monopolies over medical care: discover why and what consequences can bring us.

  • Environmental
    • All
    • Environmental reports
    Proyecto BIOVEGE: De residuos hortofrutícolas a bioplásticos y compuestos bioactivos

    From Fruit and vegetable residues to sustainable bioplastics and additives natural products: all the conversion process in the Project BIOVEGE.

  • English
    • Spanish
  • Login
Retail
  • Biomedical
    • All
    • Biomedical interviews
    • Biomedical news
    • Biomedical reports
    Europa lleva la delantera en el desarrollo y comercialización de los medicamentos biosimilares: nuevas licencias y un gran ahorro en el horizonte

    Europe leads the way in the development and commercialization of biosimilar medicines: new licenses and huge savings on the horizon

    Biotecnología al servicio de la agricultura sostenible: Biorizon biotech y los proyectos H2020 SABANA y BACAGRO

    New tests of early cancer detection will allow the implementation of better treatments through personalized medicine

    La medicina predictiva utiliza el asesoramiento genético para medir la probabilidad de las enfermedades que se pueden padecer y cómo prevenirlas

    Predictive medicine uses the genetic counselling to measure the likelihood of illnesses that can be suffer and how to prevent them

  • Agri-food
    • All
    • Agri-food news
    • Agri-food reports
    Agrobiotechnology: the keys of the sector that mostly is going to impact in our future

    Agrobiotechnology: the keys of the sector that mostly is going to impact in our future

    Alimentos funcionales para suplir la deficiencia de la enzima intestinal DAO: el remedio contra las migrañas

    Functional food to supply the deficiency of the intestinal enzyme DAO: the remedy against migraines

    Los biopesticidas de esta biotech chilena permiten combatir el perjudicial hongo Botrytis cinerea.

    These biopesticides from this Chilean biotech allow to combat harmful fungus Botrytis cinerea.

  • Industrial
    • All
    • Industrial news
    Horizonte H2020 se extiende hasta 2027: Descubre cómo se optimizan los proyectos de investigación con esta estrategia

    Horizon H2020 extends to 2027: Discover how are optimized research projects with this strategy

    El proyecto europeo IBISBA 1.0 hace que la biotecnología industrial abra sus puertas a la investigación.

    The European project IBISBA 1.0 makes that industrial biotechnology opens its doors to the investigation.

    La posibilidad de oro en España para su mejora bioeconómica tiene nombre: “Biorrefinerías”.

    Golden opportunity in Spain for its bioeconomic improvement has name: “Biorefineries”.

  • Bioinformatics
    • All
    • Bioinformatics news
    • Bioinformatics reports
    La STATegra Summer School llega a su fin tras 5 intensivos días de aplicación de técnicas bioinformáticas a la integración de datos ómicos

    The STATegra Summer School comes to its end after 5 days of intensive application of bioinformatics techniques for omics data integration

    Let us go deep into the biological systems technology, what is its potential and which tools are now affordable

    Let us go deep into the biological systems technology, what is its potential and which tools are now affordable

    La atención médica virtual extiende sus redes y surgen monopolios sobre la asistencia médica: descubre el por qué y qué consecuencias puede traernos.

    Virtual health care extends its networks and arise monopolies over medical care: discover why and what consequences can bring us.

  • Environmental
    • All
    • Environmental reports
    Proyecto BIOVEGE: De residuos hortofrutícolas a bioplásticos y compuestos bioactivos

    From Fruit and vegetable residues to sustainable bioplastics and additives natural products: all the conversion process in the Project BIOVEGE.

  • English
    • Spanish
No Result
View All Result
InspiraBiotech
No Result
View All Result

Winning the game to neurodegenerative diseases: the new BN201 drug of Bionure powers neuroprotection and remyelination.

David Valero by David Valero
June 5, 2018
in Biomedical, Biomedical news
Reading Time: 6 mins read
0
Home Biomedical
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

BN201 is the first  SGK2 selective agonist in its class that promotes remyelination and neuroprotection, by offering a solution that changes the playing field in the treatment of neurodegenerative diseases, giving us certain advantages to begin to combat them.

Has recently been initiated its phase 1 clinical trial in the United Kingdom, and in order to speed up and tie well each place in the development of this new drug, the company Bionure has reconstituted its Board of Directors and has been added to the prominent neuro-ophthalmologist Dr. Craig Smith as new Medical Director, with which them expect to successfully manage this process.

YOU MAY ALSO LIKE

Europe leads the way in the development and commercialization of biosimilar medicines: new licenses and huge savings on the horizon

New tests of early cancer detection will allow the implementation of better treatments through personalized medicine

Bionure It is a biotechnology company with headquarters in Barcelona which develops neuroprotective agents to treat neurodegenerative rarediseases in the field of ophthalmology. Mainly is centered in the field of Acute Optic Neuritis (AON), and Optic Neuromyelitis (NMO). Since its founding in 2009 by Dr. Pablo Villoslada and Albert G. Zamora, and emerged as a spin-off of the Hospital Clínic of Barcelona, Bionure has obtained for its main candidate BN201 the orphan drug designation for the Optic Neuritis in Europe and the United States, and has shown evidence of neuroprotection and remyelination in different animal models.

Currently, there is no therapeutic drugs on the market for Acute Optic Neuritis (AON), and Optic Neuromyelitis  (NMO). Patients are treated with corticosteroids and immunomodulators that reduce inflammation but not repaired the nerve damage. BN201 has shown neuroprotective activity and stimulates remyelination through differentiation of oligodendrocytes progenitor cells (OPCs) in mature oligodendrocytes and thus promoting the formation of myelin sheath around axons.

Both of these actions make BN201 as promising solution for patients with AON and NMO and open a way to treat other neurodegenerative diseases such as multiple sclerosis (MS).

It should be noted that the optic neuritis is often a first sign of the development of multiple sclerosis (MS), so that the drug has the potential to be used in the future for the treatment of other neurodegenerative diseases without specific therapies as the latter.

BN201 is the first in its class that promotes cell survival and the endogenous natural repair through the activation of SKG2, an  intracellular serine/threonine kinase that plays a crucial role in the response of the neurons to stress and their survival. The Phase 1 clinical trial aims to investigate the safety, tolerability and pharmacokinetics of single- and multiple-dose of BN201 in healthy volunteers. The results are expected for the end of the year and the company’s plan is to begin a phase 2a trial in 2019.

“The start of the Phase I clinical trials is an important milestone for Bionure. We are excited to see that BN201 advances in the clinic, a step closer to patients,” said Sea Masso , managing director of Bionure.

The beginning of the clinical trial marks the culminating point of the next stage initiated by Bionure, and for their development has renewed its Board of Directors. It is now chaired by Guy P. Nohra , founder of High Life Sciences, co-founder of Alta Partners (with 2 billion $ collected between 1996 and 2006) and expert investor LS (Life Science). In addition, Paul Frohna , MD, Rajiv Mahadevan and Josep Herrero have joined the board together with Montserrat Vendrell High-LS. Salut Monràs , Bionure investor, and Sea Masso, managing director of Bionure, complete the Board.

But the renewal of the Board has not been the only change in the company. The neuro-ophthalmologist Craig Smith, until now a member of the Scientific Advisory Board of Bionure, joins the company as the Chief Medical Officer (CMO). Dr. Smith brings its long experience in companies such as Genentech and Novartis, teams in neuroscience and ophthalmology. It is principal adviser to the Bill and Melinda Gates Foundation and throughout his career he has directed several research on optic neuritis and multiple sclerosis.

“BN201 has proven benefits in several animal models of damage, including the demyelination, inflammation and neurodegeneration, and it has been shown that promotes the protection neuronal and axonal myelin repair,” said Dr. Smith. “We believe that BN201 has the potential to provide a new therapeutic approach for AON, NMO and multiple sclerosis patients “.

“The addition as CMO of Dr. Craig Smith will undoubtedly give us a valuable impetus to the clinical development of BN201 “, said Guy P. Nohra, president of Bionure. 

High Life Sciences is leading a series A round of 4 million euros to finance the clinical development of BN201 for AON and NMO, diseases that affect 130.000 patients per year in the United States and Europe and that have a potential world market of around € 1.000 million / year.

 

The Acute Optic Neuritis (AON), and Optic Neuromyelitis (NMO) are eye diseases caused by an autoimmune reaction that causes inflammation and demyelination of the optic nerve (that can spread to the spinal cord and brain in NMO). Currently, patients with AON and NMO are treated with corticosteroids and immunomodulators that reduce inflammation but do not regenerate the damage of the nerve. There is a drug approved to treat AON and NMO.

Multiple sclerosis is a unpredictable disease, often disabling disease of the central nervous system that interrupts the flow of information within the brain and between the brain and the body. In progressive forms of MS  chronic neurodegeneration occurs that results in the progression of a invalidating state. So far, the therapies that are effective for relapse of MS have shown between limited to no efficacy in MS.

This disease affects more than 400,000 people in North America, approximately 500,000 in Europe and 2.5 million in all over the world.  The average onset of the disease is 30 years, and like many autoimmune diseases, have a inbalance distribution by gender and affects women more often than men, this is also valid for multiple sclerosis, representing the number of affected women double than men.

For all these reasons, new therapies that allow us to protect and repair the nervous system are a promising approach for people with progressive forms of multiple sclerosis and other neurodegenerative diseases, for whom there are so few treatment options.

 

Image credits BlueRingMedia, Designua, CI Photos, Andrii Vodolazhskyi, ellepigrafica, Ralwel, CLIPAREA l Custom media /shutterstock.com

ShareTweetShare
Previous Post

Esta prometedora inmunoterapia CAR-T inicia su desarrollo en España.

Next Post

Últimos avances en medicina personalizada: OncoDNA y MD Anderson aúnan fuerzas en el diagnóstico genómico del cáncer.

David Valero

David Valero

David Valero Torresano, fundador de Inspira Biotech. Graduado en Biología y máster en Oncología Farmacéutica, ha trabajado como Especialista de producto para una Multinacional Japonesa del sector Biomédico líder mundial en hematología, y ha desarrollado estancias y colaboraciones de investigación en diferentes Hospitales y Centros de Investigación de España. De marcado espíritu emprendedor y creativo ha participado en el programa YUZZ para jóvenes emprendedores presentándose con el proyecto Dreamalife, consistente en el desarrollo y la introducción en el mercado de nuevos sistemas de diagnóstico in vitro basados en la tecnología CRISPR-Cas9 para el desarrollo de la medicina personalizada. Contacta a través de: dvalero@inspirabiotech.com

Next Post
Últimos avances en medicina personalizada: OncoDNA y MD Anderson aúnan fuerzas en el diagnóstico genómico del cáncer.

Recent advances in personalized medicine: OncoDNA and MD Anderson join forces in the genomic diagnosis of cancer.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Search

No Result
View All Result

Recent News

JBI 2018: el escaparate de las últimas novedades en bioinformática

JBI 2018: a window to the latest developments in bioinformatics

November 19, 2018
Biotecnología al servicio de la agricultura sostenible: Biorizon biotech y los proyectos H2020 SABANA y BACAGRO

Biotechnology at the service of sustainable agriculture: Biorizon biotech and the H2020 SABANA and BACAGRO projects

May 21, 2019
Biotecnología al servicio de la agricultura sostenible: Biorizon biotech y los proyectos H2020 SABANA y BACAGRO

Alternatives to CRISPR-cas9: the new genetic editing tools, more precise and safer

May 21, 2019

Medio de información líder en el sector biotecnológico de Sudamérica y España. Toda la actualidad en ciencia, tecnología y bioeconomía. 

  • Home
  • Biomedicina
  • Agroalimentaria
  • Industrial
  • Bioinformática
  • Medioambiental
Menu
  • Home
  • Biomedicina
  • Agroalimentaria
  • Industrial
  • Bioinformática
  • Medioambiental
  • Home
  • Biomedicina
  • Agroalimentaria
  • Industrial
  • Bioinformática
  • Medioambiental
Menu
  • Home
  • Biomedicina
  • Agroalimentaria
  • Industrial
  • Bioinformática
  • Medioambiental

© Inspirabiotech – All rights reserved, 2021.

No Result
View All Result
  • Biomedical
  • Agri-food
  • Industrial
  • Bioinformatics
  • Environmental
  • English
    • Spanish

© 2021 Inspira Biotech, todos los derechos reservados.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In